

## **BioLight Announces First IOPTiMate™ System Sale in Hong Kong**

**Earlier this year upon CFDA approval to the IOPTiMate™ system, a strategic distribution agreement was signed with a target of at least 100 systems in China - the world's largest glaucoma markets**

**TEL AVIV (September 10, 2014) - BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY)**, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announces the first sale of an IOPTiMate™ system in Hong Kong.

A medical center in Hong Kong purchased the IOPTiMate™ system following a successful trial, and an additional IOPTiMate™ system has been installed on a trial basis at a second medical center in Hong Kong.

The sale of this first system in Hong Kong is the result of an intensive marketing campaign by BioLight in Asia for the IOPTiMate™ system as part of the Company's focus on markets with unmet needs for better solutions to treat glaucoma. BioLight recently began marketing to leading physicians and medical centers in China after receiving approval in March 2014 from the China Food and Drug Administration (CFDA) to market and sell the IOPTiMate™ system.

Suzana Nahum-Zilberberg, BioLight's chief executive officer, said, "Medical centers in Hong Kong are held in high regard across China, and the completion of this first IOPTiMate™ system sale represents a vote of confidence in BioLight and supports continued penetration to the Asian markets. The sale of the system and the additional installation in Hong Kong, as well as the regulatory approval and distribution agreement we entered into earlier this year in China and marketing activity underway in additional Asian countries, represent important steps in the implementation of our strategy to penetrate Asian markets."

The IOPTiMate™ system is based on CO<sub>2</sub> laser technology that enables the performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball, thus allowing for substantial reductions in post-operative complications and use of eye drops compared with alternatives.

### **About Glaucoma:**

Glaucoma, which created pressure within the eye causes damage to the optic nerve that may lead to full or partial blindness, is considered the second most common cause of blindness worldwide. According to estimates commonly accepted in the field, there are now about 67 million people worldwide that suffer from the disease. Glaucoma is usually a chronic disease requiring lifelong treatment, and based on assessments, the global market for drug therapy and surgery, is estimated at \$4 billion annually.